ArticleClinical and experimental hepatology2019
Decellularized liver bioscaffold: a histological and immunohistochemical comparison between normal, fibrotic and hepatocellular carcinoma.
Article in Clinical and experimental hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 7 citations in OpenAlex.
- Review
- Diamond Nanofilm Normalizes Proliferation and Metabolism in Liver Cancer Cells.Nanotechnology, science and applications · 2021Article
- Emerging trends in modeling human liver diseaseAPL bioengineering · 2019Article
- Recreating Tumour Complexity in a Dish: Organoid Models to Study Liver Cancer Cells and their Extracellular Environment.Cancers · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aim of the studyIncreasing demand for liver transplantation represents an important health burden. Decellularized liver bioscaffold can be a suitable alternative for whole organ transplantation. However, various pathologies can affect the structure of decellularized scaffolds.This work discusses differences between hepatic fibrosis (HF), hepatocellular carcinoma (HCC) and normal decellularized liver bioscaffolds. MATERIAL AND
methodsMurine models of HF and HCC were created, livers from normal, HF and HCC were decellularized, and evaluation of decellularization was done using morphological, histological and DNA analysis examination. Also, immunohistochemical staining using collagen, laminin, fibronectin and alphafetoprotein was done. Deposition area and intensity of the used immunohistochemical staining in liver capsules and the staining deposition thickness in the blood vessels and hepatic capsule walls were measured for comparison between the three models.
resultsNormal, HF and HCC livers were decellularized efficiently as confirmed by histological and DNA estimation. HCC decellularized samples showed significantly higher collagen, fibronectin and laminin deposition in both capsule and blood vessels, followed by HF decellularized samples, which also showed the highest thickness of laminin deposition in both capsule and blood vessels, then the normal model, which recorded the lowest value. Alphafetoprotein positive cells were absent in normal and HF, with rare cells in HCC.
conclusionsEven pathologic livers, HF and HCC, can be efficiently decellularized, showing normal morphology and architecture. However, HCC and HF showed significantly higher deposition of extracellular matrix proteins: collagen, fibronectin and laminin. The impact of these differences on physiological and immunological functions of the bioscaffold requires recellularization experiments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.